STAT
DECEMBER 4, 2024
LONDON — The U.K. will start offering Eli Lilly’s weight loss drug next year, but will restrict the medicine to people with the greatest need as the country tries to adapt to new ways of treating obesity amid surging demand. Health authorities in the U.K. recommend tirzepatide, sold there as Mounjaro, for people with a body mass index of more than 35 and at least one related health condition.
PharmaVoice
DECEMBER 4, 2024
Dr. Marty Makary’s conflicts of interest could come into question before he is confirmed as the next FDA commissioner.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
DECEMBER 4, 2024
Year after year, more Americans are affected by health care data breaches. Though health savings accounts, pharmacies, and major hospitals have all been attacked in 2024, a single data breach accounted for the vast majority of people’s data being exposed: Change Healthcare. Multiple times this year, lawmakers have questioned health care industry experts about why the massive and disruptive Change Healthcare breach was allowed to happen , and what the government should do to improve health
Drug Topics
DECEMBER 4, 2024
No medications were associated with improved quality of life or reduced headache duration.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmaVoice
DECEMBER 4, 2024
Four companies that refreshed their mission and public persona with a new look.
Drug Topics
DECEMBER 4, 2024
Pain, fatigue, and sleep disturbances are common symptoms with rheumatic diseases.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
DECEMBER 4, 2024
Researchers explored literature on the health benefits of the 4 main functional dietary components—prebiotics, probiotics, synbiotics, and postbiotics.
Fierce Pharma
DECEMBER 4, 2024
AstraZeneca’s Daiichi Sankyo-partnered antibody-drug conjugate Enhertu has made it onto China’s national insurance program despite the star med being a part of an ongoing investigation in the count | AstraZeneca’s Daiichi Sankyo-partnered antibody-drug conjugate Enhertu has made it onto China’s national insurance program despite the star med being a part of an ongoing investigation in the country.
Drug Topics
DECEMBER 4, 2024
The drugs were compared over a 72-week study period.
Pharma Marketing Network
DECEMBER 4, 2024
Table of Contents Sr# Headings 1 Introduction 2 Digital Transformation in Pharma Marketing 3 Patient-Centric Marketing 4 Personalized Healthcare Campaigns 5 The Role of AI and Machine Learning 6 Leveraging Social Media Platforms 7 Data-Driven Decision Making 8 Omnichannel Marketing Strategies 9 The Power of Influencer Marketing 10 Navigating Regulatory Challenges 11 Sustainability in Pharma Marketing 12 Conclusion 13 FAQs Introduction Pharma marketing is undergoing a revolution.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
DECEMBER 4, 2024
ATX101 from Allay Therapeutics is designed for use following total knee arthroplasty in adults and has shown positive results in multiple studies.
European Pharmaceutical Review
DECEMBER 4, 2024
A new report, ‘ Enhancing the role of UK medicine regulation ’ by the Association of the British Pharmaceutical Industry (ABPI) explores the key role that regulatory excellence has in driving innovation and early treatment access for patients, as well bringing investment into the UK. It provides key recommendations aimed at rebuilding the UK’s world-class reputation in regulatory science, medicines’ development and licensing, driving economic growth, ensuring earlier patient access to innovative
Drug Topics
DECEMBER 4, 2024
A recent study found that, among older adults who are generally healthy and not at high risk for type 2 diabetes, Vitamin D3 supplementation does not significantly reduce the risk of developing the disease.
Fierce Healthcare
DECEMBER 4, 2024
UnitedHealth Group abruptly ended its investor day event on Wednesday morning as new reports surfaced that the CEO of its health plan division had been fatally shot. | UnitedHealth Group abruptly ended its investor day event on Wednesday morning as news reports surfaced that the CEO of its health plan division had been fatally shot.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Topics
DECEMBER 4, 2024
AMA released its 2024 Overdose Epidemic Report and presented key findings from the past year.
Fierce Healthcare
DECEMBER 4, 2024
Risks with AI-enabled health technologies topped the list of the ECRI Institute's annual ranking of health technology hazards. | A well-known safety group debuted its annual report that lays out the top 10 health technology risks for the upcoming year. The risks of AI perpetuating bias or hallucinating answers to medical questions tops the list of risks for 2025.
pharmaphorum
DECEMBER 4, 2024
Genmab has licensed another anti-glycan antibody for cancer from UK biotech Scancell as it continues to expand its in-house pipeline.
STAT
DECEMBER 4, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hullo. Lots today on GLP-1s: First we see tirzepatide outperforming semaglutide in a head-to-head study in obesity. Also, compounding pharmacies fire back at Novo Nordisk for its assertion that GLP-1 drugs are too difficult to compound.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
DECEMBER 4, 2024
Examining challenges in pharmacy school is necessary to solve current problems in the workforce.
STAT
DECEMBER 4, 2024
The hormone leptin was discovered 30 years ago to much fanfare. Scientists hoped that leptin, which regulates body fat, could pave the way for obesity treatments. The results in mice were hailed as “miraculous,” and Amgen licensed the hormone for $20 million from Rockefeller University. But its initial promise failed to pan out, as treatments mimicking leptin in the body didn’t spur weight loss.
Pharmacy Times
DECEMBER 4, 2024
The decline was attributed to continued adherence to infection prevention and control measures.
STAT
DECEMBER 4, 2024
Conservative Supreme Court justices appeared skeptical Wednesday of arguments that they should intervene in Tennessee’s ban on gender-affirming care for minors. The court heard arguments in U.S. v. Skrmetti that the state’s ban discriminated against transgender minors and denied them constitutionally equal protections. Outside the courthouse, in a sonic representation of the cultural divisiveness around the issue, advocates for gender-affirming care access blasted Bad Bunny a
pharmaphorum
DECEMBER 4, 2024
Discover how the automation of flow cytometry is transforming cancer diagnosis and treatment for breast, prostate, endometrial, pancreatic, kidney, and melanoma cancers. Explore the latest advancements in the field.
Fierce Pharma
DECEMBER 4, 2024
Merus’ week keeps getting better. | The FDA had originally pushed its decision back by three months after a November manufacturing-related delay.
STAT
DECEMBER 4, 2024
In an unexpected move, the U.S. Patent & Trademark Office has withdrawn a controversial proposal that was designed to prevent pharmaceutical companies from abusing the patent system. Specifically, the proposed rule was crafted to stem the use of so-called patent thickets , which are wielded by drug companies to delay the arrival of lower-cost generic medicines in the marketplace.
Fierce Healthcare
DECEMBER 4, 2024
The Centers for Medicare & Medicaid Services has successfully negotiated agreements with two drug manufacturers to participate in the newly created Cell and Gene Therapy Access Model. | The two drugs treat sickle cell disease, the stated first priority of the new CMS model set to begin in January.
Fierce Pharma
DECEMBER 4, 2024
With AstraZeneca’s former international chief, Leon Wang, under investigation in China, the company has promoted an AZ veteran to fill the post. | With AstraZeneca’s former international chief, Leon Wang, under investigation in China, the company has promoted an AZ veteran to fill the post. The British giant has appointed Iskra Reic, Ph.D., as its new international executive vice president.
Fierce Healthcare
DECEMBER 4, 2024
The healthcare staffing market continues to consolidate as staffing solution companies look to expand their reach through M&A deals. | Digital staffing company Aya Healthcare plans to acquire Cross Country Healthcare for $18.61 per share in cash in a transaction valued at approximately $615 million.
Fierce Pharma
DECEMBER 4, 2024
With the purchase of a plant in the Czech Republic, Novo Nordisk is saying “jak se máš” to hundreds of new employees—and expanding its production footprint along the way. | Novavax is selling its 150,000-square-foot recombinant protein facility in Bohumil, Czech Republic, to Novo Nordisk for a total of $200 million. Under the deal, which is expected to close by Dec. 30, Novo will get its hands on the production site, support buildings and the plant’s entire existing workforce, which stands at ar
pharmaphorum
DECEMBER 4, 2024
Brain-computer interfaces, such as Elon Musk's Neuralink, have the potential to revolutionise precision medicine and transform how we understand and treat the brain. Learn more about this groundbreaking technology and its implications in healthcare.
STAT
DECEMBER 4, 2024
Greetings from STAT’s London outpost, with reporter Andrew Joseph here filling in for Ed. No particularly exciting flavored coffee to offer you today, but we did have a mulled cider last night that put us right into the festive spirit. Now, though, as ever, it’s back to the grind. Some tidbits below to help you start your day. … Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo Nordisk, in a head-to-head
pharmaphorum
DECEMBER 4, 2024
Applied Therapeutics gets a warning letter from the FDA over a trial of rare disease drug govorestat, which was rejected by the agency last week
Fierce Pharma
DECEMBER 4, 2024
Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care Excellence (NICE) has laid out plans for an unprecedented phased rollout that | Roughly 220,000 people in England will be eligible for the drug during the three-year launch phase. Afterward, officials plan to open access to a wider group of obesity patients, which numbers in the millions in England.
Expert insights. Personalized for you.
131 
Let's personalize your content